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STUDY PROTOCOL Open Access
Cognitive rehabiliation for Parkinson's
disease dementia: a study protocol for a
pilot randomised controlled trial
John V Hindle1,2*, Tamlyn J Watermeyer3, Julie Roberts4, Anthony Martyr5, Huw Lloyd-Williams6, Andrew Brand2,
Petra Gutting7, Zoe Hoare2, Rhiannon Tudor Edwards6 and Linda Clare4
Abstract
Background: There is growing interest in developing non-pharmacological treatments to address the cognitive
deficits apparent in Parkinson’s disease dementia and dementia with Lewy bodies. Cognitive rehabilitation is a
goal-oriented behavioural intervention which focuses on improving everyday functioning through management of
cognitive difficulties; it has been shown to be effective in Alzheimer’s disease. To date, no studies have assessed its
potential efficacy for addressing the impact of cognitive impairment in people with Parkinson’s disease or dementia
with Lewy bodies.
Methods/design: Participants (n = 45) will be recruited from movement disorders, care for the elderly and memory
clinics. Inclusion criteria include: a diagnosis of Parkinson’s disease, Parkinson’s disease dementia or dementia with Lewy
bodies according to consensus criteria and an Addenbrooke’s Cognitive Examination – III score of≤ 82. Exclusion criteria
include: a diagnosis of any other significant neurological condition; major psychiatric disorder, including depression,
which is not related to the patient’s Parkinson’s disease and unstable medication use for their physical or cognitive
symptoms. A single-blind pilot randomised controlled trial, with concurrent economic evaluation, will compare the
relative efficacy of cognitive rehabilitation with that of two control conditions. Following a goal-setting interview, the
participants will be randomised to one of the three study arms: cognitive rehabilitation (eight weekly sessions), relaxation
therapy (eight weekly sessions) or treatment as usual. Randomisation and treatment group allocation will be carried out
by a clinical trials unit using a dynamic adaptive sequential randomisation algorithm. The primary outcomes are patients’
perceived goal attainment at a 2-months post-intervention assessment and a 6-months follow-up. Secondary outcomes
include patients’ objective cognitive performance (on tests of memory and executive function) and satisfaction with goal
attainment, carers’ perception of patients’ goal attainment and patients’ and carers’ health status and psychosocial
well-being, measured at the same time points. Cost-effectiveness will be examined to explore the design of a larger
cost-effectiveness analysis alongside a full trial.
Discussion: This pilot study will evaluate the application of cognitive rehabilitation for the management of cognitive
difficulties associated with Parkinson’s disease dementia and dementia with Lewy bodies. The results of the study will
inform the design of a fully powered randomised controlled trial.
Trial registration: ISRCTN16584442 DOI 10.1186/ISRCTN16584442 13 April 2015
Keywords: Cognitive intervention, Cost-effectiveness, Quality of life, Parkinsonism
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Background
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder which affects around 160 per 100,000 people in
the UK. PD presents with motor symptoms of slowness,
stiffness and tremor but is also associated with a spectrum
of non-motor symptoms. These symptoms may be auto-
nomic (swallowing, dribbling, constipation, sweating, urin-
ary problems, dizziness) or neuropsychiatric (cognitive and
behavioural impairment) in nature [1]. Neuropsychiatric
symptoms predominate as PD progresses, with at least
80 % of people living with PD for more than 20 years fulfill-
ing a dementia diagnosis [2]. Related to PD dementia is
dementia with Lewy bodies (DLB), a condition whereby
cognitive impairment precedes or occurs simultaneously
with the development of the motor symptoms of PD [3]. A
recent systematic review of 19 population-based and 10
clinic-based studies reported the mean prevalence of DLB
to be 4.2 % and 7.5 % of all dementia cases in community
(n = 2,178) and secondary care (n = 3,144) samples, respect-
ively [4]. The neuropsychological profiles of PD dementia
and DLB are similar and show subcortical or cortical pat-
terns of impairment, with marked deficits in executive
function, attention, visuospatial and memory abilities [5].
Patients’ cognitive impairments may have a significant im-
pact on their own health, social care and quality of life as
well as that of their carers [6, 7]. Care services are tasked
with supporting the functional independence of these pa-
tients through alleviating or managing their neuropsychi-
atric and motor symptoms. This co-ordination may require
input from both psychiatric and movement disorder spe-
cialists to address the complex needs of these conditions.
There is increasing interest in the effects of non-
pharmacological interventions on cognitive functioning in
neurological and psychiatric conditions. The efficacy of
non-pharmacological therapies in Alzheimer’s disease (AD)
and other dementias has been systematically studied, but it
is not clear what the evidence is for efficacy in PD. In a
systematic review of efficacy of non-pharmacological ther-
apies for AD, recommendations were made for cognition-
focused and multi-component interventions [8]. While cog-
nitive training, the repeated practice of specific cognitive
tasks, has not been found effective for people with mild
dementia, cognitive rehabilitation (CR) has shown prelimin-
ary promise [9]. CR is a more individualised approach in
which strategies to address personally relevant goals are
devised and implemented [10]. The aim of rehabilitation is
to enable people who are experiencing disability resulting
from illness or injury to function at their optimum level,
and ‘cognitive rehabilitation’ refers to the rehabilitation of
people who have cognitive impairments. Therefore, CR
aims to help people with early-stage dementia make the
most of their memory and cognitive functioning despite the
difficulties they are experiencing [11]. CR involves identify-
ing and addressing individual needs and goals, which may
require strategies for taking in new information or methods
of compensating such as using memory aids. Activities may
be targeted at improving individual cognitive deficits, com-
pensating for the deficits, or developing adaptive methods
to promote independence in instrumental activities of daily
living. CR has been shown to be effective in AD in a single-
blind randomised controlled trial comparing CR with relax-
ation therapy (RT) and treatment as usual (TAU) [12]. All
participants were able to identify goals and rate their own
performance and satisfaction with performance. CR pro-
duced significant improvements in goal performance and
satisfaction, whereas there was no change in the other
groups. The trial ’Goal-oriented cognitive rehabilitation in
early-stage dementia: multi-centre single-blind randomised
controlled trial (GREAT)’ has been funded by the HTA
(HTA reference 11/15/04) and is currently underway [13].
This trial (ISRCTN21027481) aims to obtain definitive
evidence about whether goal-oriented CR is a clinically
effective and cost-effective intervention for people with
early-stage AD, vascular or mixed dementia and their
carers, but it does not include PD dementia or DLB.
Pharmacological treatment for the cognitive-behavioural
symptoms associated with PD dementia and DLB includes
the use of acetylcholinesterase inhibitors. However, due to
their possible side effects (such as tremor, syncope or
bradycardia) [14], these drugs may be unsuitable for many
patients. There is therefore a need to consider non-
pharmacological treatments which may help support the
management of dementia in PD and DLB. In a recently
completed systematic review of non-pharmacological
therapy for enhancing cognition in PD, there were no
studies assessing the effects of non-pharmacological
interventions in PD dementia or DLB [15]. Similarly,
published economic evaluations have focused on
modelling the cost-effectiveness of pharmacological
treatments for PD [16]. The choice of interventions
needs to reflect what people with dementia and fam-
ily members say troubles them and consider the help
that would be beneficial in daily life. CR is a therapy
which potentially addresses these issues by empower-
ing people with dementia and family members to
identify the goals of their own treatment.
This is the first trial of a cognition-focused interven-
tion in PD dementia and DLB and the first study of CR
in PD dementia and DLB. The feasibility of this type of
cognitive intervention in AD is already established [12].
Therefore, this pilot study seeks to gain an indication of
possible effect sizes for the primary outcomes as they
are applied in the context of PD and DLB. It also aims
to assess the appropriateness of the current secondary
outcome measures, and establish other parameters for a
future full trial, such as the appropriate method of meas-
uring costs and effects for a cost-effectiveness analysis.
CR will be compared with treatment as usual and with
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an active control condition involving relaxation therapy,
providing the same amount of therapist time and attention.
The hypothesis is that goal performance will improve sig-
nificantly in the CR group compared with the relaxation
therapy or treatment as usual groups. The other objectives
of the pilot study are as follows:
(i) To assess the usefulness of outcome measures,
particularly the ratings of goal attainment, and
provide information on effect sizes to inform power
calculations for a definitive multi-centre randomised
controlled trial of CR in PD dementia and DLB.
(ii)To explore the usefulness of routine involvement of
therapists in the management of cognitive problems
in these conditions to improve access to
psychological therapies.
(iii)To gain a preliminary indication of the transfer of
treatment effects into everyday life for the patient.
(iv)To conduct a pilot assessment of cost-effectiveness
which will support the development of a larger trial
providing definitive evidence on cost-effectiveness.
Methods/design
Study settings
Participants will be recruited from movement disorders
and memory clinics within the Betsi Cadwaladr University
Health Board (BCUHB), Wales, UK. Data collection will
take place in the participants’ homes to accommodate
possible fatigue and physical disability as well as to reflect
the context in which cognitive difficulties will be experi-
enced and managed in their everyday lives.
Ethics and governance
Ethical approval for the study has been obtained from
the Wales Research Ethics Committee 5 (13/WA/0340).
Informed written consent will be obtained from all par-
ticipants (patients and carers) prior to entry into the
trial. As potential participants will be in the early stages
of dementia, they are expected to have the capacity to
consent to participation, and loss of capacity to consent
during the course of participation is expected to be very
infrequent. On entry to the trial, participants will be
asked whether, should they lose capacity to consent, they
are willing to continue to be included in the trial and to
have their data used.
Sample size
As this is a pilot study, it is not intended to be fully pow-
ered for detection of statistically significant effects, but is
intended to provide information that will inform the sam-
ple size calculation for a full randomised trial. Evidence
from a pilot trial using the same design for participants
with AD [12] indicates that 24 people in each group gave
a standardised effect size > 1 post intervention with 7 %
attrition. Through collaboration with the Clinical Trials
Unit, North Wales Organisation for Randomised Trials in
Health (NWORTH), it was agreed that 15 in each condi-
tion will provide enough information about the variability
of the outcome and likely attrition rate within the popula-
tion to inform the sample size calculation. The target
sample size will therefore be 45 in total recruited from
across the target population (Fig. 1). Studies show a preva-
lence of dementia in people with PD of 30 %. There are
approximately 1,500 people with PD attending the move-
ment disorder clinics in BCUHB, giving a likely prevalence
of 450 people with dementia with approximately 150–200
fulfilling the inclusion criteria. PD dementia constitutes
5 % of all people with dementia, whereas DLB is more
common, constituting up to 20 % of referrals for dementia
in specialist centres [17]. DLB is less common in general
memory clinics in BCUHB and may be under-diagnosed
(personal communication from Professor Bob Woods) but
is more often seen in the movement disorder clinics.
Taking these factors into account, the number of eligible
people with DLB in BCUHB is likely to be 100, bringing
the total eligible population to 250–300.
Randomisation
Randomisation will be completed by NWORTH using a
dynamic adaptive sequential randomisation algorithm [18].
Allocation will be on an equal ratio between the three
groups, stratifying for diagnosis (DLB/PD), gender and age
(≤69, 70+). Researchers collecting follow-up data will be
blind to the randomisation outcome.
Participants
Inclusion criteria
Participants will have either a diagnosis of PD according
to the UK PD Brain Bank Diagnostic Criteria [19] and a
diagnosis of PD dementia according to the Movement
Disorder Society consensus criteria [20, 21] or a diagno-
sis of DLB according to the consensus criteria [22]. Par-
ticipants will have mild to moderate dementia, indicated
by an Addenbrooke’s Cognitive Examination – III (ACE-
III) [23] score ≤82. Participants will ideally have a carer
or family member who is willing to participate, but this is
not an absolute requirement. Where participants are using
medication for their parkinsonism and/or cognitive symp-
toms (including acetylcholinesterase inhibitors), this use
should be stable for four weeks prior to commencement
with no changes planned for the duration of the trial. Any
unplanned changes in medication during the trial will be
documented.
Exclusion criteria
Exclusion criteria are lack of stability of PD medications,
cognitive enhancers or psychotropic medication, substan-
tial additions to medication in the four weeks before the
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trial or planned changes during the period of the trial,
other major psychiatric disorder not related to PD, major
depression and other significant neurological disease.
Goal setting
All participants will collaboratively agree on problem areas
or areas that they would like to manage better, formulated
in the form of up to three personal rehabilitation goals
using the Bangor Goal-Setting Interview (BGSI) [24]. They
will all rate their own performance on these goals at initial
and follow-up assessments, but only the CR group partici-
pants will work with a therapist to address these goals.
Interventions
CR with the therapist
Goals identified at the initial assessment will be communi-
cated to the therapist, who will use them as the starting
point for therapy and further operationalise and refine them
if necessary. Eight individual one-hour sessions of CR will
be delivered at home over 2 months. Carers will be involved
in part of each session where possible. Goals will be intro-
duced one at a time, in a flexible manner depending on rate
of progress. The participant, with the carer (where avail-
able), will work on the selected goals between sessions
following an agreed schedule of activities. The therapist will
use a variety of evidence-based strategies and supporting
components dependent on the nature of the goals set (see
Table 1 for examples of possible goals and strategies). Strat-
egies for managing practical situations and cognitive diffi-
culties as well as anxiety symptoms will be introduced
across the sessions. These sessions will build on partici-
pants’ existing abilities and emphasise a problem-solving
approach to goal attainment, where steps to success are
specified and possible solutions are tested. Compensatory
strategies may be used (for example, calendars, diaries,
reminders) as well as restorative strategies for retaining
new information or improving recall (such as mnemonics
or spaced retrieval). Progress with each goal will be
reviewed and the strategies adopted will be adjusted as ne-
cessary on a weekly basis. In-session ratings of goal per-
formance will be made by participants, carers and the
therapist to evaluate progress. The therapist is a qualified
occupational therapist working within NHS Wales and is
experienced in providing neurorehabilitation interventions
Fig. 1 CORD PD Study CONSORT-style flowchart. Recruitment began in April 2015 and will continue until May 2016. The study end date is January 2017
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for adult patient populations. Trial-specific training is pro-
vided on an ongoing basis, and the therapist’s adherence to
the treatment protocols will be monitored through therapy
logs and regular supervision sessions.
Comparators
CR will be compared with relaxation therapy (RT) and
treatment as usual (TAU). RT is included as an active
control condition involving equivalent therapist time and
attention, since PD and related conditions are known to
be very susceptible to placebo effects by modulating dopa-
mine release in relation to expectation [25]. RT will con-
sist of eight individual sessions of one hour’s duration in
participants’ own homes based on the eight- session
protocol used in the AD pilot study [12]. After an initial
‘getting to know you’ session where the therapeutic model
is explained, each session has a theme which includes
music, pictures, radio and television, sensory stimulation
and humour before a final consolidation. Each session in-
cludes consolidation of the last one, a mood checklist and
some homework. TAU will consist of usual medication
and any other services apart from specific programmes of
CR or other cognition-focused intervention. TAU may in-
clude routine monitoring by the movement disorder clinic
or memory clinic, information provision, attendance at
drop-in groups or support groups, or carer participa-
tion in support groups. Participants in the treatment
conditions will also have access to any such resources
that they might use over the course of the trial; the
use of such resources will be noted by the researcher
at the study visits.
Outcomes
Primary outcomes
Participants’ performance on goals identified through the
BGSI is rated with the researcher at the beginning and at
the follow-up visits. These ratings of goal performance are
the primary between-group comparators. The BGSI [24]
is a structured interview in which respondents are asked
to identify areas of their daily activities that are difficult to
do to their own satisfaction, and in which they would like
to see improvements. For each goal, performance is rated
on a 1 – 10 scale (1 = unable to perform; 10 = fully able to
perform) and mean levels of performance are calculated
by summing the individual goal ratings and dividing by
the number of goals. The participants’ ratings will be
made at the initial assessment, at the end of the interven-
tion period (or equivalent time for TAU group), and at
6 months post-randomisation.
Secondary outcomes
The assessment of secondary outcomes will assist in deter-
mining the most appropriate outcome measures to be used
for a larger trial. For people with PD dementia, these cover
the domains of cognition, mood, behaviour, everyday func-
tional activity, motor severity, quality of life, self-efficacy
and carer ratings (where available) of patients’ performance
on goals identified during the BGSI. Within-group data
from CR sessions on goal setting and performance will be
assessed to give information on factors such as the types of
goals that participants choose and which types of goals are
addressed most effectively through the therapy. Also, for
the CR group, patients, their carers and the therapist will
Table 1 Examples of goals and strategies employed for cognitive rehabilitation
Goal Strategies employed
“I will be able to use the iPad to send emails” Compensatory: Use cue card for step-by-step instructions. Use
of iPad stylus pen is easier than finger. Practice alongside carer
or therapist.
Restorative: Action-based learning: keep iPad and cue card
visible to prompt use. Use flowchart to break activity into
smaller steps.
“I will be able to find my purse, keys, hearing
aid and reading glasses”
Compensatory: Identify places for items to be left. Place
prompt cards in other likely places where participant leaves
items to encourage appropriate placement of items. Place
prompt card by front door to ensure participant has items
before leaving house. Use colour to support object recognition:
coloured cord put on glasses; coloured ribbon put on purse.
“I will be sociable during mealtimes and appear
to take an interest in conversation rather than
just concentrating on eating”
Compensatory: Hearing assessment and new hearing aid.
Notebook to record information participant could use in
conversation.
Restorative: Increasing awareness of other peoples’ perception
of the participant. Active listening alternately with eating and
putting knife and fork down to make eye contact, listen and
converse.
Note: Adapted into a table from Johns, R., Page, P., Pool, J., Besso, E., Evans, S., Green, J., Tranah, A., Clare, L. (2015, July). Goal-oriented cognitive rehabilitation:
improving the experience of dementia. Poster presented at the 39th College of Occupational Therapists Annual Conference, Brighton, UK.
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make in-session ratings of goal attainment to provide con-
current evidence regarding changes in goal performance.
Differences between these ratings of the patient’s goal at-
tainment will also be examined across the rater groups.
Carers’ outcomes include quality of life, stress and health.
Regarding cognition, global cognition will be measured
using the ACE-III [23]. Assessments of executive function
will be the Trail Making Test (TMT) and the letter fluency
tests from the Delis-Kaplan Executive Function System
(DKEFS) [26]. Attention will be assessed using the Test of
Everyday Attention (TEA) [27]. Memory will be assessed
using the Rivermead Behavioural Memory Test (RBMT)
[28], Story Recall subtest.
Mood will be assessed using the Hospital Anxiety and
Depression Scale (HADS), which contains subscales for
anxiety and depression and is validated in PD [29].
Behavioural assessment will include delusions and hallu-
cinations measured using the Neuropsychiatric Inventory
Questionnaire (NPI-Q) [30]. The Unified Parkinson’s Dis-
ease Rating Scale (UPDRS) [31] will be used to assess the
motor symptoms of parkinsonism in PD and DLB (part
111) and also to assess function and activities of daily living.
Quality of life will be assessed in PD and DLB using the
abbreviated Parkinson’s Disease Questionnaire (PDQ-8)
[32] and, in order to have a direct comparison, the World
Health Organisation Quality of Life – BREF (WHOQOL-
BREF) [33], which has been validated in PD [34, 35] will
also be used with carers.
In order to assess a general sense of perceived self-
efficacy, the potential to influence one’s situation through
one’s own actions, the General Self-Efficacy Scale (GSE)
[36] will be used.
The BGSI also requires carers to rate the patients’ level
of performance on a 1 – 10 scale (1 = unable to perform;
10 = fully able to perform). Carer ratings will be recorded
at the baseline, post-intervention and follow-up re-
searcher visits.
For the CR group only, a simplified goal attainment
scaling procedure [37] will be used to obtain in-session
ratings of the patient’s goal attainment by the partici-
pant, the carer and the therapist. These will be obtained
at the first, fourth and eighth (final) therapy sessions.
Carers’ stress will be assessed using the 15-item
dementia-specific Relatives Stress Scale (RSS) [38].
Service receipt during the intervention period, including
dementia-specific services, monitoring, and interventions
provided by movement and memory clinics, will be docu-
mented for all participants. All participants will be free to
access services such as those offered by Parkinson’s UK,
and the extent of this will be recorded.
Cost-effectiveness will be piloted using measures of
health status, the EQ-5D-3 L [39]. We will develop and
use a Client Service Receipt Inventory (CSRI) [40] specific
to this patient group that can be used later in a full trial to
assess health care utilisation. Other information collected
will include gender, age, the relationship between the per-
son with PD dementia and their carer and whether they
live together, age of onset of PD, PD dementia, or DLB,
Hoehn and Yahr PD severity [41]. Medication, educational
level, social class, and co-morbidities will be recorded to
examine effects of demographic and social variables on
treatment efficacy.
Procedures
The baseline assessment will be conducted once partici-
pants have given informed consent. All participants will
engage in a goal-setting interview at the baseline visit.
Participants will then be randomised and results of the
randomisation will be sent to the therapist. Participants
allocated to CR or RT will receive eight weekly visits from
the therapist over a 2-month period. The post-intervention
assessment for all participants will be conducted 2 months
after randomisation. The final follow-up assessment will
take place 6 months after randomisation.
The researcher taking the measures will be blind to allo-
cation, as will the data analysts. Blinding is achieved as
follows: following the completion of the baseline visits, the
researcher triggers randomisation through a secure web-
based system hosted by NWORTH. This system random-
isation is performed independently of the data analysis team
procedures. The outcome of the randomisation event is
emailed to the therapist only. The therapist contacts the
participants, informing them as to which treatment arm
they have been allocated. The importance of maintaining
blinding will be emphasised in the training for both re-
searcher and therapist. Since participants will be aware of
their treatment allocation, they will be asked not to reveal
to the researcher whether or not they were visited by the
therapist. Following each follow-up assessment, the re-
searcher will record to which condition she believes the
participant has been allocated and will rate her level of
certainty regarding this allocation. If participants overtly
reveal their allocation to the researcher, this will be noted.
Sensitivity analyses will determine whether these ratings or
knowledge influenced the scoring of participant data. Ana-
lyses will be adjusted to counterbalance any evident bias.
Data management and analysis
Quantitative research data will be collected and recorded
onto paper-based questionnaire booklets and will be
entered via a web interface to the MACRO participant
measures database held at NWORTH. Initial data man-
agement and cleaning will be conducted by the research
team in the study centre, and the secondary cleaning,
preparation and extraction of the datasets for analysis
will be conducted by NWORTH statisticians. Analysis
will be completed for each outcome measure at post-
intervention (2 months) and at the 6-months follow-up
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using an analysis of covariance model, with baseline
scores as a covariate, allocated group as the condition
factor and the stratification variables as fixed factors.
Confidence intervals will be calculated for the standar-
dised mean difference.
Cost-effectiveness analysis
Based on the Medical Research Council guide to the
evaluation of complex interventions [42], we will con-
duct a pilot cost-effectiveness analysis to explore how
best to collect information on intervention costs and
service use by this specific group of participants and re-
late this information to primary and secondary outcome
measures. We will take a broad public sector, multi-agency
perspective, mapping out relevant stakeholders and the full
potential range of possible costs and consequences to be
measured. This will identify potential areas for cost-savings
in the long-term management of people with Parkinson’s
disease dementia and dementia with Lewy bodies. We will
examine the feasibility of using the EQ-5D-3 L (researcher
administered) to provide a pilot cost per quality-adjusted
life year (QALY) calculation. We will make best use of
routine service utilisation, cost data and national unit cost
data. The researcher-administered CSRI, specially tailored
using the Database of Instruments for Resource Use Meas-
urement (DIRUM) database of CSRIs [43], will gain further
information about the type and frequency of service use.
We will examine whether a cost consequence or cost utility
analysis would be most appropriate for extension to a full
trial.
Discussion
This study will provide preliminary indications of effi-
cacy for CR in the management of dementias associated
with Parkinson’s disease. In addition, the study will pro-
vide information on the appropriateness of the current
outcome measures and will pilot cost-effectiveness mea-
sures, producing estimates of relative cost-effectiveness.
The results of the study will support the selection of
outcome measures and the estimation of parameters for
a larger RCT of CR in PD dementia.
There are no known risks associated with CR. It is
possible that some participants may find it challenging to
confront their difficulties, but the therapist will provide
support as they engage in this process, and the intervention
protocol incorporates attention to managing emotional
reactions. As this is a short pilot trial and there have been
no other trials of CR in PD or DLB, it is not considered
unethical to withhold CR from the comparator groups. The
research team will be trained to be alert to any concerns
about participants’ well-being. If there are serious concerns
about a participant, they will be referred, wherever possible
with the participant’s permission, to the clinician respon-
sible for the participant’s care. Blinding of the researcher,
who assesses participants’ outcomes, will be maintained
through strict procedures. Any deviation from these proce-
dures will be recorded, and blinding success will be exam-
ined at the end of the study. As this is a single-blind study,
and participants are aware of their treatment allocation, this
may introduce bias through demand characteristics. An
active control condition (RT) will help assess if any im-
provements found for the experimental group (CR) resulted
from placebo effects. A key component of this pilot trial is
to establish whether CR shows indications of effectiveness
for PD dementia or DLB [13]. As CR will be conducted by
a therapist in a naturalistic setting (in the patients’ own
homes), the pilot will assess the practicalities of its intended
delivery and direct strategies for its implementation in fu-
ture studies or care practice.
The results of this study will contribute to the devel-
opment of non-pharmacological care approaches to cog-
nitive impairment in PD, promoting patients’ functional
independence, improving their well-being and that of
their carers. The majority of movement disorder clinics
in the UK do not have immediate access to psychological
services; the results of this work may potentially foster
future co-operation of multidisciplinary teams for PD
services in NHS Wales and beyond.
Trial status
The CORD-PD trial started on 1 January 2015. Recruit-
ment commenced in April 2015 and will continue until
May 2016. The end date for the trial is January 2017.
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Questionnaire; NWORTH: North Wales Organisation for Randomised Trials in
Health; PD: Parkinson’s disease; PDQ-8: the abbreviated Parkinson’s Disease
Questionnaire; QALY: Quality-adjusted life year; RBMT: Rivermead Behavioural
Memory Test; RSS: Relatives Stress Scale; RT: relaxation therapy;
TAU: treatment as usual; TEA: Test of Everyday Attention; TMT: Trail Making
Test; UPDRS: Unified Parkinson’s Disease Rating Scale; WHOQOL-BREF: World
Health Organisation Quality of Life – BREF.
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